John Peter Fischer

USPTO Granted Patents = 26 (Patent Applications = 16)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 15)

Average Co-Inventor Count = 6.6

ph-index = 6

Forward Citations = 276(Granted Patents)

Location History:

Hawthorne, NJ (US) (1980)
Allen Park, MI (US) (1986)
Longmont, CO (US) (2004 - 2024)
Boulder, CO (US) (2014 - 2024)

Company Filing History:

Mirati Therapeutics, Inc.

Cogent Biosciences, Inc.

patents

6. 1 out of 4,177

Abbott Laboratories Corporation

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1980-2025

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12351581 - Compounds for FGFR inhibition (2025-07-08),

2. 12281122 - PI3K inhibitors (2025-04-21),

3. 12187721 - Protein tyrosine phosphatase inhibitors (2025-01-07),

4. 11964989 - KRas G12D inhibitors (2024-04-23),

5. 11932633 - KRas G12C inhibitors (2024-03-19),

6. 11884664 - Protein tyrosine phosphatase inhibitors (2024-01-30),

7. 11634417 - Protein tyrosine phosphatase inhibitors (2023-04-25),

8. 11548888 - KRas G12C inhibitors (2023-01-10),

9. 11453683 - KRas G12D inhibitors (2022-09-27),

10. 11267812 - KRAS G12C inhibitors (2022-03-08),

11. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

12. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

13. 10689377 - KRas G12C inhibitors (2020-06-23),

14. 10633381 - KRas G12C inhibitors (2020-04-28),

15. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

Certainly! Here is an article about inventor John Peter Fischer:

Title: Unveiling the Innovations of John Peter Fischer

Introduction:

John Peter Fischer, a distinguished inventor based in Boulder, Colorado, has left an indelible mark in the realm of biopharmaceutical innovations. With a penchant for pioneering solutions in the field of cancer research, Fischer has amassed a remarkable portfolio of 19 patents, showcasing his unwavering commitment to advancing medical science.

Latest Patents:

Fischer's latest patents focus on cutting-edge developments in cancer treatment. One notable invention involves KRas G12D inhibitors - compounds designed to inhibit the activity of KRas G12D, thereby offering novel avenues for combating cancer. Additionally, his work on Protein Tyrosine Phosphatase inhibitors underscores his dedication to addressing hyperproliferative diseases through innovative therapeutic approaches.

Career Highlights:

Having traversed the corridors of esteemed companies, Fischer has honed his expertise at Array Biopharma Inc. and Mirati Therapeutics, Inc. His tenure at these organizations has been marked by groundbreaking discoveries and groundbreaking advancements in the field of biopharmaceuticals, solidifying his reputation as a trailblazer in the industry.

Collaborations:

Collaborating with visionaries such as Jay Bradford Fell and Mark Joseph Chicarelli, Fischer has fostered a collaborative environment where innovation thrives. Through synergistic partnerships, Fischer and his colleagues have propelled cutting-edge research and development initiatives, pushing the boundaries of scientific innovation.

Conclusion:

In conclusion, John Peter Fischer stands as a beacon of ingenuity in the realm of biopharmaceutical innovations. His relentless pursuit of breakthrough solutions in cancer research has not only transformed the treatment landscape but has also inspired a new wave of possibilities in the fight against hyperproliferative diseases. Fischer's trailblazing spirit serves as a testament to the transformative power of innovation in shaping a brighter future for healthcare.

This text is generated by artificial intelligence and may not be accurate.